REVIEW PAPER
High-risk HPV test in cervical cancer prevention – present and future
 
More details
Hide details
1
Student’s Scientific Association, Oncological Surgery Department, Medical University, Lublin, Poland
2
Oncological Surgery Department, Independent Public Teaching Hospital No.,1 in Lublin; Medical University, Lublin, Poland
CORRESPONDING AUTHOR
Natalia Zarankiewicz   

Student's Scientific Association, Oncological Surgery Department, Medical University of Lublin, Lublin, Poland
 
J Pre Clin Clin Res. 2020;14(3):80–84
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Cervical cancer is the fourth most common cancer among women. It is related to persistent HPV infection. In order to improve diagnostic methods, a lot of research has been focused on detecting HPV DNA. A test known as a high-risk HPV test or HPV primary screening provides very encouraging results.

Objective:
The aim of this review is to present the actual knowledge about the possibilities of cervical cancer screening methods. Particular attention is paid to the question concerning the effectiveness of detecting viral DNA as a screening programme, compared to pap smear.

State of knowledge:
The HPV primary screening has higher sensitivity than the cervical smear test and it is able to detect lower-stage lesions, which are considered clinically irrelevant. Nonetheless, many HPV infections recede naturally. Therefore, relying only on the results of this test may expose women to unnecessary colposcopies and stress. Due to this fact, women under 30 years should not be screened with the hrHPV test. In view of its limitations, the HPV primary screening strategy is still tested worldwide as a pilot project. In Poland in 2019, a pilot project with the hrHPV test started at the National Institute of Oncology.

Conclusions:
Detecting viral DNA has its advantages and disadvantages. Further research is still required, but the hrHPV test has a great opportunity to become one of the main screening programmes worldwide, or at least, a valuable addition to cervical smear test.

ABBREVIATIONS
HPV – human papillomavirus; DNA – Deoxyribonucleic acid; hrHPV test- high-risk HPV test; WHO – World Health Organization; CIN3 – cervical intraepithelial neoplasia, grade 3; USPSTF – The US Preventive Services Task Force; CIN2 – cervical intraepithelial neoplasia, grade 2; CIN2+ – cervical intraepithelial neoplasia, grade 2 or worse, including CIN3; LBC – liquid-based cytology; CIN3+ – CIN3 or worse, including invasive cervical cancer; FDA – Food and Drug Administration; ATHENA – Addressing the Need for Advanced HPV Diagnostics; ASC-US – Atypical Squamous Cells of Undetermined Significance; NILM – Negative for Intraepithelial Lesion or Malignancy
Zarankiewicz N, Zielińska M, Kosz K, Kuchnicka A, Ciseł B. High-risk HPV test in cervical cancer prevention – present and future. J Pre Clin Clin Res. 2020; 14(3): 80–84. doi: 10.26444/jpccr/126432
 
REFERENCES (29)
1.
Tomassino M. The human papillomavirus family and its role in carcinogenesis. Seminars in Cancer Biology. 2014; 26: 13–21. doi: 10.1016/j.semcancer.2013.11.002.
 
2.
Araldi RP, Sant’Ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, et al. The human papillomavirus (HPV)-related cancer biology: An overview. Biomed Pharmacother. 2018; 106: 1537–1556. doi: 10.1016/j.biopha.2018.06.149.
 
3.
Arbyn M, Antilla A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document. Ann Oncol. 2010; 21(3): 448–458. doi: 10.1093/annonc/mdp471.
 
4.
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136(2): 189–197. doi: 10.1016/j.ygyno.2014.11.076.
 
5.
Centrum Onkologii – Instytut im. Marii Curie-Skłodowskiej. Pilotaż HPV. https://www.coi.pl/profilaktyk... (access: 30.12.2019; 03.08.2020).
 
6.
World Health Organization. Human papillomavirus (HPV). wht.int/immunization/diseases/... (access: 30.12.2019).
 
7.
Rositch AF, Koshiol J, Hudgens M, Razzaghi H, Backes DM, Pimenta JM, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013; 133(6): 1271–1285. doi: 10.1002/ijc.27828.
 
8.
Araldi RP, Assaf SMR, de Carvalho RF, Carvalho MACR, Souza JM, Magnelli RF, et al. Papillomaviruses: a systematic review. Genet Mol Biol. 2017; 40(1): 1–21. doi: 10.1590/1678-4685-GMB-2016-0128.
 
9.
Toufektchan E, Toledo F. The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure. Cancers (Basel) 2018; 10(5): 135. doi: 10.3390/cancers10050135.
 
10.
Hu Z, Zhu D, Wang W, Li W, Jia W, Zeng X, et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet. 2015; 47(2): 158–163. doi: 10.1038/ng.3178.
 
11.
Nowak-Markwitz E. Onkologia Ginekologiczna. In: Bręborowicz GH. Położnictwo i ginekologia. Vol.2. Ed. 2, Warsaw; 2015. p. 197.
 
12.
Sawaya GF, Smith-McCune K, Kuppermann M. Cervical Cancer Screening. More Choices in 2019. JAMA 2019; 321(20): 2018–2019. doi: 10.1001/jama.2019.4595.
 
13.
Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014; 106(3): djt460. doi: 10.1093/jnci/djt460.
 
14.
Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med. 2017; 14(9): e1002388. doi: 10.1371/journal.pmed.1002388.
 
15.
https://clinicaltrials.gov/ct2... (access: 04.08.2020).
 
16.
Demarco M, Carter-Pokras O, Hyun N, Castle PE, He X, Dallal CM, et al. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. J Clin Microbiol. 2018; 56(5): 01910–17. doi: 10.1128/JCM.01910-17.
 
17.
Bansil P, Wittet S, Lim JL, Winkler JL, Paul P, Jeronimo J. Acceptability of self-collection sampling for HPV-DNA testing in low-resource settings: a mixed methods approach. BMC Public Health 2014; 14:596. doi: 10.1186/1471-2458-14-596.
 
18.
Chan KKL, Liu SS, Wei N, Ngu SF, Chu MMY, Tse KY, et al. Primary HPV testing with cytology versus cytology alone in cervical screening-Aprospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer. 2020 Jan 10. doi: 10.1002/ijc.32861.
 
19.
Aitken CA, van Agt HME, Siebers AG, van Kemenade FJ, Niesters HGM, Melchers WJG, et al. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. BMC Med. 2019; 17(1): 228. doi: 10.1186/s12916-019-1460-0.
 
20.
Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, Boztas G, Semra Turan H, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer. 2018; 142(9): 1952–1958. doi: 10.1002/ijc.31212.
 
21.
Mariani L, Igidbashian S, Sandri MT, Vici P, Landoni F. The clinical implementation of primary HPV screening. Int J Gynaecol Obstet. 2017; 136(3): 266–271. doi: 10.1002/ijgo.12065.
 
22.
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. (US Preventive Services Task Force). Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 320(7): 674–686. doi: 10.1001/jama.2018.10897.
 
23.
Sawaya GF, Sanstead E, Alarid-Escudero F, Smith-McCune K, Gregorich SE, Silverberg MJ, et al. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. JAMA Intern Med. 2019; 179(7): 867–878. doi: 10.1001/jamainternmed.2019.0299.
 
24.
https://www.americashealthrank... (access: 10.05.2020).
 
25.
Sroczynski G, Hillemans P, Siebert U. New cervical cancer policy in Germany- what is the impact on the benefit-harm balance? Value in Health. 2019; 22(3): 443. doi: 10.1016/j.jval.2019.09.240.
 
26.
Didkowska J, Wojciechowska U, Czaderny K, Olasek P, Ciuba A. Cancer in Poland in 2017. Polish National Cancer Registry 2019; Department of Epidemiology and Cancer Prevention, p. 1–30.
 
27.
Nowakowski AM, Kotarski J. Cervical cancer in Poland and in the world – in the light of incidence and mortality data. Przegl Epidemiol. 2011; 65: 75–79.
 
28.
www.gov.pl/web/zdrowie/program... (access: 03.08.2020).
 
29.
Jankowska P, Kikolska M, Kwiatkowska M, Kochman D, Głowacka M. The level of knowledge on cervical cancer among women. Innowacje Piel Nauk Zdr. 2017; 1: 22–46.
 
eISSN:1898-7516
ISSN:1898-2395